fbpx

Biosimilar Insulins Promise Patients New Choices, But Competition Is Still Lacking

Insulin prices have long been a pain point for diabetics. The big three insulin manufacturers have cut prices across their product lineups, but potential competition from other biosimilar insulins is still in earlier stages of development.

The post Biosimilar Insulins Promise Patients New Choices, But Competition Is Still Lacking appeared first on Above the Law.

Related Articles

Responses

Your email address will not be published. Required fields are marked *